Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK/PD and safety study of subcutaneous anifrolumab in adult SLE with high type I interferon and active skin disease
2016-003246-93Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Oct 2016; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2016-003246-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003246-93.